According to the Zhitong Finance App, Meida Co., Ltd. (000782.SZ) announced that the company expects a net profit loss of 48 million yuan to 65 million yuan to shareholders of listed companies in 2022, and a profit of 56.2637 million yuan for the same period last year.

Some caprolactam plants cut production in the first half of the year due to failure or the impact of the epidemic. The rise in pure benzene prices supported the strength of raw material prices. At the same time, international oil prices fluctuated sharply, driving the price of raw materials to fluctuate higher. The company adopted a strategy of keeping close to the market and operating fast in and out, while seizing production and sales of high-value-added products, keeping an eye on exchange rate fluctuations and seeking preferential tax policies. The company achieved operating profit of about 50 million yuan in the first half of the year.

Entering the second half of the year, economic data from many countries in the US, Europe, and Asia generally declined, triggering market concerns about the economic recession, dragging down market demand. Sinopec caprolactam settlement prices were drastically lowered, and export orders were insufficient. Downstream factories were pessimistic, polymerization and wire mills were under inventory pressure, and price reduction was intense. At the same time, domestic and foreign epidemics were repeated, logistics were limited, and production capacity of some of the company's subsidiaries was limited due to hot weather. Inventories increased at the end of the year, and preparations for inventory price reductions increased. Under the influence of multiple factors, there were large losses in operations. Operating losses in the second half of the year were about 10,000 yuan.